A biotech stock with strong FDA approval odds this November may see limited upside amid a full valuation and a pending lawsuit.

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, for managing cardiovascular risks in adults. This ...

This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

The US Food and Drug Administration has approved a drug that could ease menopausal hot flashes and night sweats. Developed by ...

Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.

Molecule is claimed to be made from "natural ingredients" such as dandelion root and fennel seed, but investigations tell a ...

Gabapentin has become the 5th most prescribed drug. It's also getting a bad reputation. Here's why it doesn't deserve it, ...

Ionis Pharmaceuticals, Inc. shows promise with new drug launches and a robust pipeline. Click here to read IONS stock ...

Novo Nordisk's Rybelsus gets US FDA approval for CV risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event: Plainsbo ...

Rybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events ...

Detailed price information for Amarin Corp ADR (AMRN-Q) from The Globe and Mail including charting and trades.